EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog

Yoshimi Niwano, Atsuo Iwasawa, Masahiko Ayaki

Ophthalmology and Eye Diseases · 2014

DOI: 10.4137/oed.s12445 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ophthalmology and Eye Diseases, 2014. Verfasst von Yoshimi Niwano und 2 weiteren Autor:innen. Beteiligte Einrichtung: Tohoku University Graduate School of Dentistry, Sendai, Japan. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In vitro cytotoxicity of tafluprost, which is the most recently developed anti-glaucoma prostaglandin (PG) analog, in ocular surface cells is addressed in comparison with other PG analogs. Irrespective of cell lines and models, the cytotoxicity of anti-glaucoma PG eyedrops was primarily related to the concentration of benzalkonium chloride (BAK) contained in the eyedrops as a preservative. Accordingly, preservative-free tafluprost was apparently less cytotoxic than BAK-preserved PG analogs. Furthermore, our study for cytotoxicity assays on ocular cells, conducted by comprehensive investigations covering a variety of concentrations and treatment times, which is termed the cell viability score (CVS) system, demonstrated that 0.001% BAK-preserved tafluprost was not cytotoxic, and suggested that tafluprost may even reduce the cytotoxic effect of BAK. It has been reported that adverse reactions associated with tafluprost in healthy human volunteers and patients with glaucoma include conjunctival hyperemia, eyelid pigmentation, eyelash bristles, and deepening of upper eyelid sulcus. Nonetheless, most clinical studies have demonstrated that not only preservative-free tafluprost but also BAK-preserved tafluprost is well tolerated and safe in patients with glaucoma and ocular hypertension.

Schlagwörter

Stichwörter der Autor:innen

cytotoxicityocular surface cellsprostaglandin analogsafety evaluationtafluprost

Autor:innen und Institutionen

  • Tohoku University Graduate School of Dentistry, Sendai, Japan.
  • Department of Bioengineering, Tokyo Institute of Technology, Yokohama, Japan.
  • Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.

Zitieren

APA

Niwano, Y., Iwasawa, A., & Ayaki, M. (2014). Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog. Ophthalmology and Eye Diseases. https://doi.org/10.4137/oed.s12445

Vancouver

Niwano Y, Iwasawa A, Ayaki M. Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog. Ophthalmology and Eye Diseases. 2014. doi:10.4137/oed.s12445

BibTeX
@article{Niwano2014,
  author = {Niwano, Yoshimi and Iwasawa, Atsuo and Ayaki, Masahiko},
  title = {Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog},
  journal = {Ophthalmology and Eye Diseases},
  year = {2014},
  doi = {10.4137/oed.s12445}
}
Kostenlos starten →